Abstract
Size-exclusion chromatography (SEC) separates molecules by how their hydrodynamic radius matches the pore-size distribution of the stationary phase, and it is the primary method for quantifying aggregates and fragments in biologics. Its value does not rest on the precision of a single method but on a sound mechanism, a complete chain of system-suitability and validation evidence, and orthogonal confirmation by complementary techniques (capillary electrophoresis, analytical ultracentrifugation, multi-angle light scattering). Starting from the separation mechanism, this article outlines the validation approach, compares the relevant provisions of the Chinese Pharmacopoeia 2025, the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) point by point, and focuses on boundaries in data analysis and integration that are easily overlooked: the preconditions for area normalization, the systematic underestimation of aggregates caused by co-elution, and the peak-to-valley rule when peaks are not baseline-resolved.
Keywords: size-exclusion chromatography; aggregates; fragments; hydrodynamic radius; system suitability; multi-pharmacopoeia compliance; integration
1 Introduction
The heterogeneity of a biologic is multidimensional, and aggregates and fragments belong to its "size dimension". No single technique covers every dimension: SEC is insensitive to charge variants, ion exchange resolves aggregates poorly, and the organic mobile phase of reversed-phase methods denatures the protein, so it cannot reflect purity in the native conformation. Characterizing a biologic is therefore essentially an orthogonal combination of techniques, in which SEC serves as the "primary quantitative method" for aggregates and fragments — primary in the sense that it gives the relative proportions of the size species directly, in the native state, without relying on structural assumptions.
The regulatory framework points the same way. ICH Q6B requires appropriate test procedures for attributes such as molecular weight and size and purity of biotechnological products, and encourages the use of multiple orthogonal or complementary methods; the current benchmark for method development and validation is ICH Q2(R2). This article is written for two kinds of reader: the analytical lead designing the release strategy for a new product (who needs to know where criteria and acceptance limits come from), and the analyst who runs and reviews SEC data (who needs the interpretation pitfalls and integration rules).
2 Separation principle (first principles)
2.1 Accessible pore volume determines retention
SEC separates molecules by how their hydrodynamic radius matches the pore-size distribution of the stationary phase (Figure 2). The packing consists of porous particles with a distribution of pore sizes:
- Molecules larger than the largest pores are completely excluded, travel the shortest path through the interstitial volume and elute first;
- Molecules that can freely enter the pores travel a longer path inside them and elute last;
- Intermediate-sized molecules elute in between, in proportion to the pore volume they can access.
For protein aggregates, whose radius is larger than that of the monomer, the elution order is always aggregate → monomer → fragment → small-molecule impurities. This is the mechanistic basis for SEC as the primary quantitative method for aggregates.
Scroll sideways to see the full figure →
Scroll sideways to see the full figure →
2.2 Three mechanistic limits to keep in mind
First, SEC measures hydrodynamic radius, not molecular weight. Isomers of equal radius (for example oxidized and non-oxidized monomer, or compact conformational variants) cannot be resolved, and converting retention to apparent molecular weight with a globular-protein calibration gives systematic errors for non-globular molecules such as extended fusion proteins.
Second, resolution is limited by both column efficiency and peak width. When aggregate and monomer partly co-elute, area normalization underestimates the aggregate — the fundamental reason why system suitability must lock in a resolution threshold.
Third, the mobile phase must keep the conformation stable and suppress secondary interactions. Residual silanols or ionic groups on the packing cause non-specific adsorption, lowering recovery and causing peak tailing, so salt-containing buffers are commonly used to screen electrostatic interactions.
2.3 Coupling with multi-angle light scattering
Coupled with multi-angle light scattering (MALS), SEC can measure the absolute molecular weight and radius of gyration of each peak during the separation, without relying on a calibration curve. USP 〈1430〉 and 〈1430.1〉 cover scattering-based methods in general and static light scattering in particular. The coupling is a key extension for large carriers such as adeno-associated virus (AAV): using the 260/280 nm absorbance ratio, the proportion of empty and full capsids can be estimated in a single injection (partially filled particles are difficult to distinguish separately).
3 Validation approach
3.1 System-suitability criteria
The framework for SEC system suitability is formed by ChP 2025 General Chapter 0512, USP 〈621〉 and Ph. Eur. 2.2.46. The key criteria are:
- Resolution: not less than 1.5 for the monomer–aggregate pair under the general framework; tightened to not less than 2.0 for monoclonal antibodies (General Chapter 3127);
- Tailing factor: 0.8–1.8 for the main peak when quantifying by peak area (newly specified in the 2025 edition of General Chapter 0512);
- Molecular-weight check: measured molecular weight of the standard within 5% of the labelled value (product-specific);
- Injection sequence: a bracketing design — blank, system suitability, duplicate sample injections, system suitability, blank — to verify system stability.
The 2025 edition of Chapter 0512 contains several revisions (including definitions of sensitivity and signal-to-noise, repeatability requirements and relative retention time). Two bear directly on SEC: the peak-to-valley ratio is added (for peaks that are not baseline-resolved), and when resolution is calculated from widths at half height, the coefficient is written uniformly as 1.18 (the previous edition wrote 2/1.70, which is numerically equivalent, so the criterion is not tightened). The key point remains: the quantitation limit for aggregates is bounded by resolution, and when resolution is insufficient the area-normalized aggregate value is systematically low — this cannot be compensated by adding injections.
3.2 Validation parameters and lifecycle
Chromatographic methods are validated according to ICH Q2(R2) and ChP General Chapter 9101. For purity methods such as SEC the emphasis is on precision (area RSD), stability-indicating capability (change in peak response for forced-degradation samples) and specificity (separation of degradation peaks from the main peak); accuracy is usually addressed through agreement with orthogonal methods and recovery, which is the key difference from assay methods. The quantitation limit is the concentration giving a signal-to-noise ratio of 10; empirically, at a resolution of about 1.5 the quantitation limit for dimer is of the order of 0.1%–0.5% of total protein, and it varies with resolution and signal-to-noise — it is not a fixed constant.
4 Compliance with the Chinese, US and European pharmacopoeias
4.1 Chinese Pharmacopoeia 2025
- General Chapter 0512 (high-performance liquid chromatography): the unified system-suitability framework; this edition adds the peak-to-valley ratio and writes the resolution coefficient as 1.18;
- General Chapter 0514 (size-exclusion chromatography): specific provisions on SEC conditions and system suitability;
- General Chapter 3127 (size variants of monoclonal antibodies, Method 2): theoretical plates for the main peak not less than 4900, main-peak tailing factor not more than 1.4, resolution between aggregate and main peak not less than 2.0, and between main peak and fragment not less than 1.8;
- General Chapter 3121 (polymers in human albumin): resolution between monomer and dimer greater than 1.5 and tailing factor of the monomer peak 0.95–1.40 — stricter than the general window in 0512, showing that general criteria applying "unless otherwise specified" are tightened in individual monographs.
4.2 United States Pharmacopeia (USP)
- 〈621〉 Chromatography: the unified chromatographic system-suitability framework; resolution coefficient for half-height widths 1.18 (2022 harmonized version);
- 〈129〉: analytical procedures for recombinant therapeutic monoclonal antibodies, a dedicated analytical route for mAbs;
- 〈1430〉/〈1430.1〉: analytical methodologies based on scattering phenomena (general) and static light scattering.
4.3 European Pharmacopoeia (Ph. Eur., EDQM)
- 2.2.30 Size-exclusion chromatography: the chapter specific to SEC;
- 2.2.46 Chromatographic separation techniques: the corresponding system-suitability framework, with a symmetry factor of 0.8–1.8 (consistent with USP 〈621〉 and ChP 2025); monographs may set tighter windows, and the general chapter states that the monograph prevails.
4.4 Comparison of the three pharmacopoeias
| Provision | ChP 2025 | USP | Ph. Eur. (EDQM) |
|---|---|---|---|
| System-suitability framework | General Chapter 0512 | 〈621〉 | 2.2.46 |
| SEC-specific chapter | General Chapter 0514 | No dedicated chapter; 〈129〉 includes an SEC procedure for mAbs | 2.2.30 |
| Resolution coefficient (half-height widths) | 1.18 (revised in 2025) | 1.18 (harmonized 〈621〉) | Consistent (2.2.46) |
| Symmetry / tailing factor | T 0.8–1.8 (new in 2025; for peak-area quantitation) | 0.8–1.8 | 0.8–1.8 (monographs may be stricter) |
| Peak-to-valley ratio p/v | New in 2025 (when not baseline-resolved) | — | As specified in the monograph |
| Light scattering | — | 〈1430〉/〈1430.1〉 | — |
5 Data analysis and integration
This is where SEC data review most often goes wrong.
5.1 Three preconditions for area normalization
Area-normalized results are quantitatively meaningful only when all three conditions are met:
- All peaks are adequately resolved;
- Response factors are similar (when response differs markedly, for example for glycosylation variants, normalized area ≠ molar proportion);
- The injected amount is within the linear range.
5.2 Systematic underestimation of aggregates by co-elution
When aggregate and monomer partly co-elute, area normalization systematically underestimates the aggregate. This is the fundamental reason why system suitability must lock in a resolution threshold (monomer/aggregate ≥ 1.5) — when resolution is insufficient, adding injections does not help.
In addition, when the injection volume exceeds about 1%–2% of the column volume, peaks broaden, aggregate–monomer resolution falls and normalized results deviate systematically. The criterion is that the peak width and plate count of the system-suitability solution at the main-peak retention volume match those obtained when the method was established — not merely that resolution passes the threshold.
Scroll sideways to see the full figure →
5.3 Baseline, peak-to-valley ratio and integration of unresolved peaks
- When two peaks are not baseline-resolved, use the peak-to-valley ratio (p/v) as the criterion rather than forcing a perpendicular drop at the valley;
- Fix and record the baseline, so that raising or lowering it does not change the assignment of peak area;
- Isomers of equal radius (for example oxidized and non-oxidized monomer) co-elute in SEC and cannot be distinguished by integration; confirm them with orthogonal methods (CE-SDS, mass spectrometry).
5.4 Data integrity and control of manual integration
Under data-integrity requirements, SEC integration parameters should not simply use software defaults; they should be established during method development and validated. Manual integration must be controlled by an SOP with the reason recorded, and automated integration is preferred. Every manual change to a baseline or drop line must leave an audit trail.
6 Applications and the orthogonal division of labour
In the size dimension, SEC and its complementary methods supplement rather than replace one another:
- With CE-SDS (capillary electrophoresis): SEC gives native-state relative proportions, CE-SDS gives denatured, subunit-level purity, and the two cross-check each other for aggregates and fragments;
- With analytical ultracentrifugation (AUC): SEC gives relative proportions, AUC gives an absolute size distribution;
- Coupled with MALS: absolute molecular weight and radius of gyration, without reliance on a calibration curve.
Typical applications include mAb release (aggregates and fragments), AAV vectors (dual-wavelength SEC as a quick screen of the empty-capsid ratio, with absolute values confirmed by AUC or charge-detection mass spectrometry) and fusion proteins (assessing apparent-molecular-weight bias caused by extended conformations). SEC gives "relative proportions", not an "absolute size distribution"; when methods disagree, first check differences in sample preparation and concentration conditions before questioning the method itself.
Scroll sideways to see the full figure →
7 Conclusions
As the backbone technique of the size dimension, SEC yields trustworthy conclusions only when three design decisions are right: a sound mechanism (separation by hydrodynamic radius), a complete chain of system-suitability and validation evidence (with the source of each criterion identified), and disciplined data analysis and integration (preconditions for area normalization, underestimation by co-elution, the peak-to-valley rule and control of manual integration). SEC can carry release testing, but the reliability of its results — especially area-normalized aggregate values — must be confirmed during characterization by orthogonal methods such as electrophoresis, light scattering and ultracentrifugation.
References
Primary sources (regulations, pharmacopoeias and international guidelines)
- Chinese Pharmacopoeia Commission. (2025). Pharmacopoeia of the People's Republic of China, 2025 ed., Vol. IV. General Chapter 0512: High-performance liquid chromatography; General Chapter 9101: Guidelines for validation of analytical procedures. Beijing: China Medical Science Press. https://2025.chp.org.cn/
- Chinese Pharmacopoeia Commission. (2025). Pharmacopoeia of the People's Republic of China, 2025 ed., Vol. IV. General Chapter 0514: Size-exclusion chromatography. https://2025.chp.org.cn/
- United States Pharmacopeia. USP General Chapter 〈621〉 Chromatography [S]. Rockville: USP, 2025.
- United States Pharmacopeia. USP General Chapter 〈129〉 Analytical Procedures for Recombinant Therapeutic Monoclonal Antibodies [S]. Rockville: USP, 2025.
- United States Pharmacopeia. USP General Chapter 〈1430〉 Analytical Methodologies Based on Scattering Phenomena—General;〈1430.1〉 —Static Light Scattering [S]. Rockville: USP.
- European Pharmacopoeia. 2.2.30 Size-exclusion chromatography [S]. Strasbourg: EDQM, 11th ed.
- European Pharmacopoeia. 2.2.46 Chromatographic separation techniques [S]. Strasbourg: EDQM, 11th ed.
- ICH. Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products [S]. ICH, 1999.
- ICH. Q2(R2): Validation of Analytical Procedures [S]. ICH, 2023.
Secondary sources (supporting literature and specific pharmacopoeial chapters)
- Porath J, Flodin P. Gel filtration: a method for desalting and group separation [J]. Nature, 1959, 183(4676): 1657–1659. DOI: 10.1038/1831657a0
- Moore J C. Gel permeation chromatography. I. A new method for molecular weight distribution of high polymers [J]. Journal of Polymer Science Part A, 1964, 2(2): 835–843.
- Chinese Pharmacopoeia 2025, Vol. IV. General Chapter 3127: Determination of size variants of monoclonal antibodies. https://2025.chp.org.cn/
- Chinese Pharmacopoeia 2025, Vol. IV. General Chapter 3121: Determination of polymers in human albumin. https://2025.chp.org.cn/
- Chinese Pharmacopoeia 2025, Vol. III. General monograph on human gene therapy products. https://2025.chp.org.cn/